Keyword: ribociclib

FDAApprovedStamp

The top 10 drug launches of 2017

Only 22 meds were greenlighted by the FDA in 2016, but no matter what tally the industry amasses this year, the crop will bring some would-be blockbusters and market disrupters.

7. LEE011

Novartis’ LEE011, also known as ribociclib, is revving up to challenge Pfizer's hot-selling Ibrance in the CDK 4/6 field. Despite some safety concerns that have worried investors, EP analysts see the prospect easily topping the blockbuster mark by 2022.
FDAApprovedStamp

The top 10 drug launches of 2017

After an unusually slow year for new drug approvals—the FDA greenlighted just 22 meds in 2016—it remains to be seen whether drugmakers can do much better in 2017. One thing’s for sure, though: No matter what total the industry tallies up this year, the crop will bring some would-be blockbusters and market disrupters.

5. Ibrance

Ibrance—the first in a new class of CDK 4/6 inhibitors—has romped away since Pfizer launched it in the U.S. in February 2015 as a combination therapy with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that has spread to another part of the body.